NEW YORK – Boston-based Aprea Therapeutics said on Thursday that it will expand patient enrollment in a Phase I clinical trial evaluating its lead drug candidate, eprenetapopt, as a frontline treatment for acute myeloid leukemia patients with TP53 mutations.